Biocon Biologics' CEO & MD Shreehas Tambe On Strong Q3, Future Demand | Partnership With Sandoz AG

Biocon Biologics has reported a remarkable 65% YoY revenue growth for Q3FY24, reaching Rs 2,483 crore. Biocon Biologics completed its transformation into a fully integrated global biosimilars enterprise in Q3FY24, operating across 120+ countries. Shreehas Tambe, CEO & MD, Biocon Biologics, discusses Q3 performance and the new partnership with Sandoz AG with BTTV's Anchor Sakshi Batra. #BioconBiologics #Q3Results